175 related articles for article (PubMed ID: 17195078)
1. CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway.
Lionello I; Mangia P; Gattinoni L; Pende D; Cippone A; Sensi M; Rigatti P; Traversari C
Cancer Immunol Immunother; 2007 Jul; 56(7):1065-76. PubMed ID: 17195078
[TBL] [Abstract][Full Text] [Related]
2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.
Gorter A; Krüse KM; Schrier PI; Fleuren GJ; van de Griend RJ
Clin Exp Immunol; 1992 Jan; 87(1):111-6. PubMed ID: 1531120
[TBL] [Abstract][Full Text] [Related]
4. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas.
Wang QJ; Hanada K; Yang JC
J Immunol; 2008 Sep; 181(6):3769-76. PubMed ID: 18768829
[TBL] [Abstract][Full Text] [Related]
6. Alloantigen-specific cytotoxic clones bearing the alpha,beta T cell antigen receptor but not CD4 or CD8 molecules.
Rivas A; Koide J; Laus R; Engleman EG
J Immunol; 1990 Jul; 145(2):470-6. PubMed ID: 2142178
[TBL] [Abstract][Full Text] [Related]
7. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-activated murine cell lines with macrophage- and B-lymphoblast-lytic activity.
Suzuki H; Ikemoto M; Yokoyama A; Kamitani T; Yamashita N; Maruyama M; Yano S
Cell Immunol; 1991 Jan; 132(1):127-39. PubMed ID: 1829651
[TBL] [Abstract][Full Text] [Related]
9. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
10. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas.
Guerra N; Guillard M; Angevin E; Echchakir H; Escudier B; Moretta A; Chouaib S; Caignard A
Blood; 2000 May; 95(9):2883-9. PubMed ID: 10779435
[TBL] [Abstract][Full Text] [Related]
11. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.
Tykodi SS; Satoh S; Deming JD; Chou J; Harrop R; Warren EH
J Immunother; 2012 Sep; 35(7):523-33. PubMed ID: 22892449
[TBL] [Abstract][Full Text] [Related]
12. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
[TBL] [Abstract][Full Text] [Related]
14. Identification of an enriched CD4+ CD8alpha++ CD8beta+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Dal Cin P; Van den Berghe H; Ceuppens JL
Int J Cancer; 1997 Apr; 71(2):178-82. PubMed ID: 9139839
[TBL] [Abstract][Full Text] [Related]
15. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
16. Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions.
Radrizzani M; Benedetti B; Castelli C; Longo A; Ferrara GB; Herlyn M; Parmiani G; Fossati G
Int J Cancer; 1991 Dec; 49(6):823-30. PubMed ID: 1835714
[TBL] [Abstract][Full Text] [Related]
17. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
Dörrschuck A; Schmidt A; Schnürer E; Glückmann M; Albrecht C; Wölfel C; Lennerz V; Lifke A; Di Natale C; Ranieri E; Gesualdo L; Huber C; Karas M; Wölfel T; Herr W
Blood; 2004 Oct; 104(8):2591-9. PubMed ID: 15231579
[TBL] [Abstract][Full Text] [Related]
18. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
[TBL] [Abstract][Full Text] [Related]
19. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
20. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.
Mitropoulos D; Kooi S; Rodriguez-Villanueva J; Platsoucas CD
Clin Exp Immunol; 1994 Aug; 97(2):321-7. PubMed ID: 8050183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
